Arca
Skip to content
Tools
Tools

Chronic myeloid leukemia

Drug research and approvals for chronic myeloid leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 145 studies of chronic myeloid leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and FDA has 15 approved and 13 open orphan designations naming it.

  • Recruiting worldwide: 145
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 15
  • EU medicines: 0

Recruiting now

Newest posted first, of 145 recruiting on ClinicalTrials.gov ↗

How its trials ended

979 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 315 whose ending is known, 37% met their primary endpoint, 3% missed it and 61% stopped early.

  • Completed, result not reported39140%
  • Ongoing17618%
  • Met its primary endpoint11512%
  • Stopped: other or unclear10411%
  • Status unknown9710%
  • Stopped: enrollment or feasibility566%
  • Stopped: sponsor or business decision131%
  • Missed its primary endpoint81%
  • Stopped: lack of efficacy81%
  • Stopped: funding71%
  • Stopped: safety4<1%

Trials authorized in Canada

The 10 newest of 13; search them all in Canada trials
Apr 1, 2026A phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in participants with chronic myeloid leukemiaTERN-701Terns PharmaceuticalsPending
Oct 26, 2023A phase 1a/1b study of ELVN-001 for the treatment of chronic myeloid leukemiaELVN-001Enliven TherapeuticsOngoing
Jun 17, 2022A phase Ib study of the pharmacokinetics, safety and efficacy of orally administered HQP1351 in subjects with refractory chronic myeloid leukemia (CML) and…Olverembatinib (HQP1351) / Lisaftoclax (APG-2575)Ascentage Pharma Group Inc.Ongoing
Mar 8, 2021An open-label, multicentre, phase 1b/2 study of safety and efficacy of KRT-232 combined with a tyrosine kinase inhibitor (TKI) in patients with relapsed or…KRT-232Kartos Therapeutics IncOngoing
Oct 8, 2015A randomized, open-label, phase 2 trial of ponatinib in patients with resistant chronic phase chronic myeloid leukemia to characterize the efficacy and safety…PonatinibTakeda Pharmaceuticals USAOngoing
Sep 3, 2015A randomized, open-label study of ponatinib versus nilotinib in patients with chronic myeloid leukemia in chronic phase following resistance to imatinibPonatinibAriad PharmaceuticalsClosed
Jan 29, 2015A phase 3, multicenter, open-label, randomized study of SGI-110 versus treatment choice (TC) in adults with previously untreated acute myeloid leukemia (AML)…Guadecitabine (SGI-110)/ Cytarabine/ AzacitidineAstex Pharmaceuticals Inc.Closed
Sep 24, 2014Treatment-free remission accomplished with dasatinib in patients with CML.DasatinibUniversity Health NetworkClosed
Jul 25, 2014An open-label, single-group clinical study to evaluate the pharmacokinetics, safety, and efficacy of omacetaxine mepesuccinate given subcutaneously as a fixed…Synribo (omacetaxine)Teva Pharmaceutical IndustriesPending
Nov 1, 2013A phase 1b dose escalation study to investigate the safety, tolerability and preliminary efficacy for the combination of dasatinib (BMS-354825) plus nivolumab…BMS-936558 (nivolumab) / BMS-354825 (dasatinib)Bristol-Myers SquibbOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 28
May 29, 2026CavhanzaTreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and…Cycle Pharmaceuticals LtdApproved
Aug 1, 2025PhyragoTreatment of pediatric patients 1 year of age and older with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in…Handa Therapeutics, LLCApproved
Nov 7, 2024DanzitenTreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and…Azurity Pharmaceuticals, Inc.Approved
Oct 29, 2024ScemblixTreatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)Novartis Pharmaceuticals CorporationApproved
Oct 29, 2024ScemblixTreatment of adult patients with previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase…Novartis Pharmaceuticals CorporationApproved
Dec 5, 2023PhyragoTreatment of adult patients with: newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase;…Handa Therapeutics, LLCApproved
Oct 29, 2021ScemblixTreatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I…Novartis Pharmaceuticals CorporationApproved
Oct 29, 2021ScemblixTreatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously…Novartis Pharmaceuticals CorporationApproved
Sep 23, 2021TasignaTreatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome…Novartis Pharmaceuticals CorporationApproved
Mar 22, 2018TasignaTASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed…Novartis Pharmaceuticals CorporationApproved
Nov 9, 2017SprycelTreatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phaseBristol-Myers Squibb CompanyApproved
Dec 14, 2012IclusigTreatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or…Takeda Pharmaceuticals U.S.A., Inc.Approved
Oct 26, 2012SynriboTreatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or…IVAX International GmbHApproved
Jun 28, 2006SprycelTreatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinibBristol-Myers Squibb CompanyApproved
May 10, 2001GleevecTreatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of…Novartis Pharmaceuticals CorporationApproved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.